Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analyst view: Terns has a consensus "Hold" from 15 analysts (1 sell, 10 hold, 3 buy, 1 strong buy) with an average 1‑year price target of about $55.14.
• Insider activity: CEO Amy L. Burroughs and other insiders sold a combined 30,108 shares over the past 90 days worth roughly $1.30M, leaving insiders with 1.50% ownership.
• Institutional ownership & stock position: Institutions own 98.26% of the stock with major funds increasing stakes, and the share price trades near its 52‑week high ($53.19) with a market cap of $6.12B and a negative P/E.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $55.1364.

TERN has been the topic of a number of research reports. William Blair lowered shares of Terns Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 7th. Citizens Jmp lowered shares of Terns Pharmaceuticals from a "market outperform" rating to a "hold" rating in a report on Thursday, March 26th. BMO Capital Markets lowered shares of Terns Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, March 26th. TD Cowen lowered shares of Terns Pharmaceuticals from a "buy" rating to a "hold" rating and set a $53.00 target price on the stock. in a report on Thursday, March 26th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Terns Pharmaceuticals in a report on Friday, March 27th.

Insiders Place Their Bets

In other news, CEO Amy L. Burroughs sold 14,583 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer directly owned 288,976 shares of the company's stock, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Emil Kuriakose sold 942 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the sale, the insider directly owned 105,673 shares in the company, valued at approximately $5,574,250.75. This represents a 0.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 30,108 shares of company stock worth $1,302,370. Insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Morgan Stanley boosted its stake in shares of Terns Pharmaceuticals by 4.7% in the 4th quarter. Morgan Stanley now owns 7,945,608 shares of the company's stock valued at $321,003,000 after purchasing an additional 356,513 shares during the last quarter. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 3rd quarter valued at $42,807,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Terns Pharmaceuticals by 40.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company's stock valued at $224,220,000 after purchasing an additional 1,611,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Terns Pharmaceuticals by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company's stock valued at $223,167,000 after purchasing an additional 964,031 shares during the last quarter. Finally, Vestal Point Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 4th quarter valued at $181,800,000. 98.26% of the stock is owned by institutional investors.

Terns Pharmaceuticals Price Performance

TERN opened at $52.97 on Tuesday. Terns Pharmaceuticals has a fifty-two week low of $2.65 and a fifty-two week high of $53.19. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of -51.42 and a beta of -0.37. The company's 50 day moving average price is $48.93 and its two-hundred day moving average price is $36.96.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. As a group, equities research analysts predict that Terns Pharmaceuticals will post -1.21 EPS for the current year.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.